Pharmacia is suing Alcon Laboratories for alleged infringement of apatent which covers the manufacture of Xalatan (latanoprost), Pharmacia's glaucoma treatment which achieved sales of $497 million in the first nine months of 2000, a 43% rise over the like, year-ealier period. Pharmacia has asked the court to declare that a competing product that Alcon is preparing to launch in the USA early this year infringes the Pharmacia patent, notes Reuters.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze